Sangamo Therapeutics Company Profile (NASDAQ:SGMO)

About Sangamo Therapeutics (NASDAQ:SGMO)

Sangamo Therapeutics logoSangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has clinical and preclinical programs in development and partnered certain programs with biopharmaceutical companies to expedite clinical and commercial development. The focus for its Company is the development of human therapeutics. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. The Company has initiated a Phase I/II clinical trial evaluating its zinc finger nuclease (ZFN) in vivo genome editing approach for the treatment of hemophilia B. In the development of its ZFP technology platform, it is focusing its resources on product development for therapeutic use in humans and on its non-therapeutic applications.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:SGMO
  • CUSIP: 80067710
  • Web:
  • Market Cap: $521.56 million
  • Outstanding Shares: 71,939,000
Average Prices:
  • 50 Day Moving Avg: $5.61
  • 200 Day Moving Avg: $4.28
  • 52 Week Range: $2.65 - $8.60
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.14
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $18.87 million
  • Price / Sales: 27.64
  • Book Value: $1.75 per share
  • Price / Book: 4.14
  • EBIDTA: ($65,520,000.00)
  • Net Margins: -388.23%
  • Return on Equity: -45.02%
  • Return on Assets: -40.02%
  • Debt-to-Equity Ratio: 0.02%
  • Current Ratio: 10.74%
  • Quick Ratio: 10.74%
  • Average Volume: 1.25 million shs.
  • Beta: 3.22
  • Short Ratio: 10.12

Frequently Asked Questions for Sangamo Therapeutics (NASDAQ:SGMO)

What is Sangamo Therapeutics' stock symbol?

Sangamo Therapeutics trades on the NASDAQ under the ticker symbol "SGMO."

How were Sangamo Therapeutics' earnings last quarter?

Sangamo Therapeutics Inc (NASDAQ:SGMO) announced its quarterly earnings results on Wednesday, May, 10th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.03. The business had revenue of $3.40 million for the quarter, compared to the consensus estimate of $4.14 million. Sangamo Therapeutics had a negative return on equity of 45.02% and a negative net margin of 388.23%. The business's revenue was down 12.8% on a year-over-year basis. During the same quarter last year, the business posted ($0.23) EPS. View Sangamo Therapeutics' Earnings History.

Where is Sangamo Therapeutics' stock going? Where will Sangamo Therapeutics' stock price be in 2017?

5 analysts have issued 12-month price objectives for Sangamo Therapeutics' stock. Their forecasts range from $4.00 to $14.00. On average, they expect Sangamo Therapeutics' stock price to reach $7.75 in the next year. View Analyst Ratings for Sangamo Therapeutics.

What are analysts saying about Sangamo Therapeutics stock?

Here are some recent quotes from research analysts about Sangamo Therapeutics stock:

  • 1. According to Zacks Investment Research, "Sangamo BioSciences, Inc. is a leader in the development of novel transcription factors for the regulation of gene expression. Transcription factors are proteins that turn genes on or off by recognizing specific DNA sequences. The Universal Gene Recognition technology platform enables the engineering of a class of transcription factors known as zinc finger DNA binding proteins. " (5/16/2017)
  • 2. Cowen and Company analysts commented, "We hosted a group lunch meeting with SGMO management this week." (3/22/2017)
  • 3. Piper Jaffray Companies analysts commented, "Today Sangamo reported 4Q16 financial results, ending the quarter with ~$143M in cash. With updated 2017 guidance on operating expenses incorporated into our model, we expect this cash runway can fund the company through 1H18. This period should include the first safety and biomarker data from early cohorts of patients treated in its open, or soon-to-be opened, clinical trials for Hem A, Hem B, MPS I, and MPS II. Although we expect these early results in late'17/early '18 to focus primarily on safety and pharmacodynamic signals of activity and thus not yet be definitive for informing pivotal programs, we nonetheless believe this progress to be critical for evaluating turn-around efforts and establishing a new era of clinical achievement for Sangamo. That said, in advance of enrollment updates and increased visibility on clinical progress for Sangamo's broadening but early pipeline, we remain on the sidelines with a Neutral rating." (2/28/2017)

Are investors shorting Sangamo Therapeutics?

Sangamo Therapeutics saw a increase in short interest in April. As of April 13th, there was short interest totalling 7,495,425 shares, an increase of 2.0% from the March 31st total of 7,345,616 shares. Based on an average daily volume of 601,287 shares, the short-interest ratio is presently 12.5 days.

Who are some of Sangamo Therapeutics' key competitors?

Who owns Sangamo Therapeutics stock?

Sangamo Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (4.36%), FMR LLC (2.27%), Granahan Investment Management Inc. MA (1.44%), Fic Capital Inc. (1.33%), Royce & Associates LP (1.06%) and Geode Capital Management LLC (0.89%). Company insiders that own Sangamo Therapeutics stock include Curt A Herberts III, Dale G Ando, Edward O Lanphier II, Henry Ward Wolff, Philip D Gregory, Ra Capital Management, Llc and William R Ringo. View Institutional Ownership Trends for Sangamo Therapeutics.

Who sold Sangamo Therapeutics stock? Who is selling Sangamo Therapeutics stock?

Sangamo Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Morgan Stanley, FMR LLC, Columbus Circle Investors, SG Americas Securities LLC, Bourgeon Capital Management LLC, Princeton Alpha Management LP and Wedbush Securities Inc.. View Insider Buying and Selling for Sangamo Therapeutics.

Who bought Sangamo Therapeutics stock? Who is buying Sangamo Therapeutics stock?

Sangamo Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Granahan Investment Management Inc. MA, United Services Automobile Association, Vanguard Group Inc., Iguana Healthcare Management LLC, Tocqueville Asset Management L.P., Parametric Portfolio Associates LLC, Highbridge Capital Management LLC and Franklin Street Advisors Inc. NC. View Insider Buying and Selling for Sangamo Therapeutics.

How do I buy Sangamo Therapeutics stock?

Shares of Sangamo Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Sangamo Therapeutics stock cost?

One share of Sangamo Therapeutics stock can currently be purchased for approximately $7.25.

Analyst Ratings

Consensus Ratings for Sangamo Therapeutics (NASDAQ:SGMO) (?)
Ratings Breakdown: 3 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.40)
Consensus Price Target: $7.75 (6.90% upside)

Analysts' Ratings History for Sangamo Therapeutics (NASDAQ:SGMO)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/16/2017WedbushReiterated RatingNeutral$6.00 -> $4.00MediumView Rating Details
3/22/2017Cowen and CompanyReiterated RatingBuyHighView Rating Details
2/28/2017Piper Jaffray CompaniesReiterated RatingNeutral$5.00N/AView Rating Details
8/5/2016Jefferies Group LLCReiterated RatingBuyN/AView Rating Details
8/4/2016Janney Montgomery ScottDowngradeBuy -> Neutral$15.00 -> $8.00N/AView Rating Details
5/3/2016Wells Fargo & CoInitiated CoverageBuyN/AView Rating Details
2/10/2016JPMorgan Chase & Co.Reiterated RatingOverweight$16.00N/AView Rating Details
(Data available from 5/27/2015 forward)


Earnings History for Sangamo Therapeutics (NASDAQ:SGMO)
Earnings by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)
Earnings History by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2017Q1 2017($0.26)($0.23)$4.14 million$3.40 millionViewN/AView Earnings Details
2/28/2017Q416($0.26)($0.14)$3.91 million$8.90 millionViewListenView Earnings Details
10/26/2016Q316($0.25)($0.27)$4.24 million$2.82 millionViewListenView Earnings Details
8/3/2016Q216($0.24)($0.38)$5.38 million$3.70 millionViewN/AView Earnings Details
5/2/2016Q116($0.24)($0.23)$5.49 million$3.94 millionViewN/AView Earnings Details
2/9/2016Q415($0.21)($0.20)$9.86 million$9.10 millionViewN/AView Earnings Details
10/28/2015Q315($0.25)($0.13)$13.09 million$8.57 millionViewListenView Earnings Details
8/5/2015Q215($0.13)($0.17)$14.72 million$8.36 millionViewListenView Earnings Details
4/22/2015Q115($0.13)($0.08)$12.50 million$13.50 millionViewListenView Earnings Details
2/10/2015Q414($0.09)($0.06)$14.50 million$15.00 millionViewN/AView Earnings Details
10/22/2014Q314($0.04)($0.11)$8.27 million$12.40 millionViewListenView Earnings Details
7/23/2014Q214($0.14)($0.10)$7.84 million$10.38 millionViewListenView Earnings Details
5/6/2014Q114($0.13)($0.12)$6.59 million$8.10 millionViewListenView Earnings Details
2/11/2014Q413($0.10)($0.13)$8.90 million$6.90 millionViewListenView Earnings Details
10/23/2013Q313($0.11)($0.11)$5.52 million$5.70 millionViewN/AView Earnings Details
7/24/2013Q2 2013($0.12)($0.10)$4.77 million$6.90 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.17)($0.13)$3.79 million$4.60 millionViewN/AView Earnings Details
2/6/2013Q4 2012($0.12)($0.07)$5.95 million$8.93 millionViewN/AView Earnings Details
10/24/2012Q312($0.14)($0.11)$3.80 million$4.90 millionViewN/AView Earnings Details
7/25/2012($0.15)($0.11)ViewN/AView Earnings Details
5/2/2012($0.16)($0.14)ViewN/AView Earnings Details
10/25/2011($0.16)($0.18)ViewN/AView Earnings Details
7/27/2011($0.16)($0.20)ViewN/AView Earnings Details
4/26/2011($0.17)($0.21)ViewN/AView Earnings Details
2/2/2011($0.19)($0.18)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Sangamo Therapeutics (NASDAQ:SGMO)
2017 EPS Consensus Estimate: ($1.12)
2018 EPS Consensus Estimate: ($1.26)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.25)($0.23)($0.24)
Q2 20172($0.29)($0.23)($0.26)
Q3 20172($0.33)($0.27)($0.30)
Q4 20172($0.32)($0.31)($0.32)
Q1 20181($0.32)($0.32)($0.32)
Q2 20181($0.32)($0.32)($0.32)
Q3 20181($0.31)($0.31)($0.31)
Q4 20181($0.31)($0.31)($0.31)
(Data provided by Zacks Investment Research)


Dividend History for Sangamo Therapeutics (NASDAQ:SGMO)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Sangamo Therapeutics (NASDAQ:SGMO)
Insider Ownership Percentage: 8.10%
Institutional Ownership Percentage: 61.87%
Insider Trades by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)
Institutional Ownership by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)
Insider Trades by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/12/2017Curt A. Herberts IIIVPSell2,639$8.02$21,164.78View SEC Filing  
8/1/2015Ra Capital Management, LlcMajor ShareholderSell27,770$12.82$356,011.40View SEC Filing  
7/30/2015Ra Capital Management, LlcMajor ShareholderSell109,590$12.42$1,361,107.80View SEC Filing  
7/29/2015Ra Capital Management, LlcMajor ShareholderSell1,407$12.41$17,460.87View SEC Filing  
7/28/2015Ra Capital Management, LlcMajor ShareholderSell60,081$12.11$727,580.91View SEC Filing  
7/25/2015Ra Capital Management, LlcMajor ShareholderSell47,429$12.31$583,850.99View SEC Filing  
7/24/2015Ra Capital Management, LlcMajor ShareholderSell124,050$12.28$1,523,334.00View SEC Filing  
7/17/2015Ra Capital Management, LlcMajor ShareholderBuy37,215$12.26$456,255.90View SEC Filing  
7/15/2015Edward O Lanphier IICEOSell25,000$10.43$260,750.00View SEC Filing  
7/13/2015Henry Ward WolffCFOSell12,000$10.00$120,000.00View SEC Filing  
7/1/2015Ra Capital Management, LlcMajor ShareholderSell82,700$16.01$1,324,027.00View SEC Filing  
6/16/2015Ra Capital Management, LlcMajor ShareholderSell250,500$16.55$4,145,775.00View SEC Filing  
6/9/2015Ra Capital Management, LlcMajor ShareholderSell83,500$15.50$1,294,250.00View SEC Filing  
6/6/2015Ra Capital Management, LlcMajor ShareholderSell135,101$14.29$1,930,593.29View SEC Filing  
6/5/2015Dale G AndoCMOSell15,000$12.29$184,350.00View SEC Filing  
6/5/2015Ra Capital Management, LlcMajor ShareholderSell115,102$14.13$1,626,391.26View SEC Filing  
6/4/2015Ra Capital Management, LlcMajor ShareholderSell70,640$13.10$925,384.00View SEC Filing  
6/3/2015Ra Capital Management, LlcMajor ShareholderSell76,833$12.86$988,072.38View SEC Filing  
6/3/2015William R RingoDirectorSell2,200$12.44$27,368.00View SEC Filing  
6/1/2015Philip D GregorySVPSell15,000$12.39$185,850.00View SEC Filing  
5/30/2015Ra Capital Management, LlcMajor ShareholderSell65,884$13.40$882,845.60View SEC Filing  
5/29/2015Ra Capital Management, LlcMajor ShareholderSell155,675$13.53$2,106,282.75View SEC Filing  
5/28/2015Ra Capital Management, LlcMajor ShareholderSell148,689$13.43$1,996,893.27View SEC Filing  
5/27/2015Ra Capital Management, LlcMajor ShareholderSell263,437$13.55$3,569,571.35View SEC Filing  
5/23/2015Ra Capital Management, LlcMajor ShareholderSell51,597$13.27$684,692.19View SEC Filing  
5/22/2015Ra Capital Management, LlcMajor ShareholderSell56,396$13.56$764,729.76View SEC Filing  
5/13/2015Ra Capital Management, LlcMajor ShareholderSell56,060$13.12$735,507.20View SEC Filing  
5/12/2015Ra Capital Management, LlcMajor ShareholderSell29,659$13.03$386,456.77View SEC Filing  
5/8/2015Ra Capital Management, LlcMajor ShareholderSell83,300$12.40$1,032,920.00View SEC Filing  
5/7/2015Ra Capital Management, LlcMajor ShareholderBuy35,736$12.09$432,048.24View SEC Filing  
5/5/2015Dale G AndoCMOSell15,000$12.29$184,350.00View SEC Filing  
5/4/2015William R RingoDirectorSell3,000$12.98$38,940.00View SEC Filing  
4/30/2015Ra Capital Management, LlcMajor ShareholderBuy124,500$13.45$1,674,525.00View SEC Filing  
4/28/2015Ra Capital Management, LlcMajor ShareholderBuy74,844$13.29$994,676.76View SEC Filing  
4/25/2015Ra Capital Management, LlcMajor ShareholderBuy166,000$13.63$2,262,580.00View SEC Filing  
4/22/2015Ra Capital Management, LlcMajor ShareholderSell352,750$14.86$5,241,865.00View SEC Filing  
4/17/2015Ra Capital Management, LlcMajor ShareholderBuy41,500$14.02$581,830.00View SEC Filing  
4/16/2015Ra Capital Management, LlcMajor ShareholderSell21,829$14.09$307,570.61View SEC Filing  
4/15/2015Edward O Lanphier IICEOSell25,000$15.33$383,250.00View SEC Filing  
4/15/2015Ra Capital Management, LlcMajor ShareholderBuy21,829$13.16$287,269.64View SEC Filing  
4/14/2015Ra Capital Management, LlcMajor ShareholderSell3,055$14.78$45,152.90View SEC Filing  
4/11/2015Ra Capital Management, LlcMajor ShareholderBuy116,992$14.48$1,694,044.16View SEC Filing  
4/10/2015Henry Ward WolffCFOSell12,000$15.31$183,720.00View SEC Filing  
4/10/2015Ra Capital Management, LlcMajor ShareholderBuy83,000$14.91$1,237,530.00View SEC Filing  
4/9/2015Ra Capital Management, LlcMajor ShareholderSell69,856$16.27$1,136,557.12View SEC Filing  
4/8/2015Ra Capital Management, LlcMajor ShareholderBuy121,876$15.49$1,887,859.24View SEC Filing  
4/7/2015Ra Capital Management, LlcMajor ShareholderBuy33,667$15.42$519,145.14View SEC Filing  
4/6/2015Dale G AndoCMOSell15,000$14.94$224,100.00View SEC Filing  
4/6/2015William R RingoDirectorSell2,200$14.95$32,890.00View SEC Filing  
4/4/2015Ra Capital Management, LlcMajor ShareholderBuy179,031$15.38$2,753,496.78View SEC Filing  
4/3/2015Ra Capital Management, LlcMajor ShareholderBuy195,126$16.61$3,241,042.86View SEC Filing  
4/1/2015Philip D GregorySVPSell15,000$15.15$227,250.00View SEC Filing  
4/1/2015Ra Capital Management, LlcMajor ShareholderSell250,000$18.01$4,502,500.00View SEC Filing  
3/28/2015Ra Capital Management, LlcMajor ShareholderBuy84,000$17.10$1,436,400.00View SEC Filing  
3/27/2015Ra Capital Management, LlcMajor ShareholderBuy256,187$17.65$4,521,700.55View SEC Filing  
3/26/2015Ra Capital Management, LlcMajor ShareholderBuy210,013$18.14$3,809,635.82View SEC Filing  
3/25/2015Ra Capital Management, LlcMajor ShareholderBuy84,000$19.42$1,631,280.00View SEC Filing  
3/21/2015Ra Capital Management, LlcMajor ShareholderBuy101,808$21.22$2,160,365.76View SEC Filing  
3/19/2015Henry Ward WolffCFOSell10,000$18.00$180,000.00View SEC Filing  
3/19/2015Ra Capital Management, LlcMajor ShareholderSell17,808$24.28$432,378.24View SEC Filing  
3/18/2015Ra Capital Management, LlcMajor ShareholderSell84,000$23.74$1,994,160.00View SEC Filing  
3/17/2015Ra Capital Management, LlcMajor ShareholderBuy52,161$23.02$1,200,746.22View SEC Filing  
3/16/2015Edward O Lanphier IICEOSell25,000$17.29$432,250.00View SEC Filing  
3/13/2015Ra Capital Management, LlcMajor ShareholderBuy71,319$22.76$1,623,220.44View SEC Filing  
3/12/2015Ra Capital Management, LlcMajor ShareholderSell123,480$23.40$2,889,432.00View SEC Filing  
3/10/2015Ra Capital Management, LlcMajor ShareholderBuy12,522$22.30$279,240.60View SEC Filing  
3/7/2015Ra Capital Management, LlcMajor ShareholderBuy258,377$22.25$5,748,888.25View SEC Filing  
3/6/2015Ra Capital Management, LlcMajor ShareholderSell61,483$24.10$1,481,740.30View SEC Filing  
3/3/2015Ra Capital Management, LlcMajor ShareholderSell84,000$18.21$1,529,640.00View SEC Filing  
3/3/2015William R RingoDirectorSell2,200$17.21$37,862.00View SEC Filing  
3/2/2015Philip D GregorySVPSell15,000$17.26$258,900.00View SEC Filing  
2/28/2015Ra Capital Management, LlcMajor ShareholderBuy42,000$18.10$760,200.00View SEC Filing  
2/27/2015Ra Capital Management, LlcMajor ShareholderSell32,196$19.37$623,636.52View SEC Filing  
2/26/2015Ra Capital Management, LlcMajor ShareholderBuy74,194$19.57$1,451,976.58View SEC Filing  
2/20/2015Ra Capital Management, LlcMajor ShareholderSell35,319$18.40$649,869.60View SEC Filing  
2/19/2015Ra Capital Management, LlcMajor ShareholderSell6,720$18.51$124,387.20View SEC Filing  
2/18/2015Ra Capital Management, LlcMajor ShareholderSell11,172$18.11$202,324.92View SEC Filing  
2/14/2015Ra Capital Management, LlcMajor ShareholderSell15,380$18.61$286,221.80View SEC Filing  
2/13/2015Ra Capital Management, LlcMajor ShareholderSell15,409$18.46$284,450.14View SEC Filing  
2/12/2015Ra Capital Management, LlcMajor ShareholderBuy42,000$18.04$757,680.00View SEC Filing  
2/12/2015Saira RamasastryDirectorSell10,000$15.00$150,000.00View SEC Filing  
2/11/2015Ra Capital Management, LlcMajor ShareholderBuy42,000$19.65$825,300.00View SEC Filing  
2/7/2015Ra Capital Management, LlcMajor ShareholderSell34,688$18.52$642,421.76View SEC Filing  
2/6/2015Ra Capital Management, LlcMajor ShareholderSell7,312$18.42$134,687.04View SEC Filing  
2/5/2015Dale G AndoCMOSell15,000$12.93$193,950.00View SEC Filing  
2/5/2015Ra Capital Management, LlcMajor ShareholderBuy42,000$18.23$765,660.00View SEC Filing  
2/3/2015William R RingoDirectorSell2,200$12.70$27,940.00View SEC Filing  
2/2/2015Philip D GregorySVPSell15,000$12.86$192,900.00View SEC Filing  
1/16/2015Edward O Lanphier IICEOSell25,000$14.22$355,500.00View SEC Filing  
1/12/2015Henry Ward WolffCFOSell12,000$15.87$190,440.00View SEC Filing  
1/5/2015Dale G AndoCMOSell15,000$15.19$227,850.00View SEC Filing  
1/5/2015William R RingoDirectorSell2,200$15.20$33,440.00View SEC Filing  
12/15/2014Edward O Lanphier IICEOSell25,000$15.40$385,000.00View SEC Filing  
12/15/2014John William LarsonDirectorSell10,000$16.28$162,800.00View SEC Filing  
12/9/2014John William LarsonDirectorSell10,000$12.00$120,000.00View SEC Filing  
12/1/2014Philip D GregorySVPSell15,000$11.68$175,200.00View SEC Filing  
11/17/2014Edward O Lanphier IICEOSell25,000$11.23$280,750.00View SEC Filing  
11/12/2014John William LarsonDirectorSell10,000$12.00$120,000.00View SEC Filing  
11/3/2014Philip D GregorySVPSell15,000$11.91$178,650.00View SEC Filing  
10/28/2014John William LarsonDirectorSell10,000$12.02$120,200.00View SEC Filing  
10/10/2014Henry Ward WolffCFOSell2,000$10.10$20,200.00View SEC Filing  
10/6/2014Dale G AndoCMOSell15,000$10.72$160,800.00View SEC Filing  
10/1/2014Philip D GregorySVPSell15,000$10.80$162,000.00View SEC Filing  
9/15/2014Edward O Lanphier IICEOSell25,000$12.14$303,500.00View SEC Filing  
9/10/2014Henry Ward WolffCFOSell2,000$12.31$24,620.00View SEC Filing  
9/5/2014Dale G AndoCMOSell15,000$12.20$183,000.00View SEC Filing  
9/4/2014John William LarsonDirectorSell10,000$12.81$128,100.00View SEC Filing  
8/15/2014Edward O Lanphier IICEOSell25,000$13.95$348,750.00View SEC Filing  
8/11/2014Henry Ward WolffCFOSell10,000$14.17$141,700.00View SEC Filing  
8/5/2014Dale G AndoCMOSell15,000$12.99$194,850.00View SEC Filing  
8/4/2014John William LarsonDirectorSell10,000$12.56$125,600.00View SEC Filing  
8/1/2014Philip D GregorySVPSell15,000$12.54$188,100.00View SEC Filing  
7/18/2014Edward O Lanphier IICEOSell25,000$12.16$304,000.00View SEC Filing  
7/10/2014Henry Ward WolffCFOSell15,000$13.26$198,900.00View SEC Filing  
7/1/2014Philip D GregorySVPSell15,000$15.66$234,900.00View SEC Filing  
6/23/2014Saira RamasastryDirectorSell5,550$15.53$86,191.50View SEC Filing  
6/16/2014Edward O Lanphier IICEOSell25,000$16.41$410,250.00View SEC Filing  
6/10/2014Henry Ward WolffCFOSell15,000$15.62$234,300.00View SEC Filing  
6/2/2014Philip D GregorySVPSell15,000$12.85$192,750.00View SEC Filing  
5/15/2014Edward Lanphier IICEOSell25,000$13.14$328,500.00View SEC Filing  
5/1/2014Philip GregorySVPSell15,000$13.68$205,200.00View SEC Filing  
4/28/2014Dale AndoCMOSell15,000$13.64$204,600.00View SEC Filing  
4/28/2014John William LarsonDirectorSell10,000$13.48$134,800.00View SEC Filing  
4/15/2014Edward Lanphier IICEOSell25,000$14.20$355,000.00View SEC Filing  
4/10/2014Henry Ward WolffCFOSell15,000$15.72$235,800.00View SEC Filing  
3/26/2014Dale AndoCMOSell15,000$18.65$279,750.00View SEC Filing  
3/21/2014Philip GregoryInsiderSell15,000$22.38$335,700.00View SEC Filing  
3/17/2014Edward Lanphier IICEOSell50,000$23.22$1,161,000.00View SEC Filing  
3/17/2014Saira RamasastryDirectorSell10,000$23.26$232,600.00View SEC Filing  
3/14/2014Steven MentoDirectorSell6,103$22.77$138,965.31View SEC Filing  
2/18/2014Edward Lanphier IICEOSell50,000$18.09$904,500.00View SEC Filing  
1/27/2014Dale AndoCMOSell15,000$18.58$278,700.00View SEC Filing  
1/10/2014Henry Ward WolffCFOSell10,000$18.69$186,900.00View SEC Filing  
1/2/2014Philip GregoryVPSell15,000$13.56$203,400.00View SEC Filing  
12/26/2013Dale AndoCMOSell15,000$14.37$215,550.00View SEC Filing  
11/15/2013Edward Lanphier IICEOSell25,000$10.11$252,750.00View SEC Filing  
11/5/2013Philip D GregoryVPSell15,000$9.60$144,000.00View SEC Filing  
10/28/2013Dale G AndoCMOSell15,000$10.39$155,850.00View SEC Filing  
10/21/2013Paul B ClevelandDirectorSell10,000$10.93$109,300.00View SEC Filing  
10/15/2013Edward O Lanphier IICEOSell25,000$11.32$283,000.00View SEC Filing  
10/10/2013Henry Ward WolffCFOSell10,000$11.28$112,800.00View SEC Filing  
10/1/2013Philip D GregoryVPSell15,000$10.54$158,100.00View SEC Filing  
9/16/2013Edward Lanphier IICEOSell25,000$11.29$282,250.00View SEC Filing  
9/10/2013Henry Ward WolffCFOSell10,000$10.86$108,600.00View SEC Filing  
9/3/2013Paul ClevelandDirectorSell7,278$10.30$74,963.40View SEC Filing  
9/3/2013Philip GregoryVPSell15,000$10.33$154,950.00View SEC Filing  
8/26/2013Dale AndoCMOSell15,000$10.04$150,600.00View SEC Filing  
8/15/2013Edward Lanphier IICEOSell25,000$10.12$253,000.00View SEC Filing  
8/13/2013Henry Ward WolffCFOSell10,000$10.00$100,000.00View SEC Filing  
8/1/2013Philip GregoryVPSell15,000$9.89$148,350.00View SEC Filing  
7/29/2013Philip D GregoryVPSell15,000$10.04$150,600.00View SEC Filing  
7/26/2013Dale G AndoCMOSell15,000$10.09$151,350.00View SEC Filing  
7/17/2013Edward O Lanphier IICEOSell25,000$10.00$250,000.00View SEC Filing  
7/17/2013Henry Ward WolffCFOSell10,000$10.00$100,000.00View SEC Filing  
7/15/2013Paul B ClevelandDirectorSell8,000$9.59$76,720.00View SEC Filing  
6/3/2013Philip D GregoryVPSell3,000$7.88$23,640.00View SEC Filing  
5/28/2013Dale G AndoCMOSell15,000$8.32$124,800.00View SEC Filing  
4/10/2013Henry Ward WolffCFOSell10,000$10.00$100,000.00View SEC Filing  
12/26/2012Dale G AndoCMOSell17,000$5.92$100,640.00View SEC Filing  
12/3/2012John William LarsonDirectorSell15,000$5.64$84,600.00View SEC Filing  
9/5/2012Dale G AndoCMOSell15,000$5.60$84,000.00View SEC Filing  
9/4/2012John William LarsonDirectorSell15,000$5.30$79,500.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Sangamo Therapeutics (NASDAQ:SGMO)
Latest Headlines for Sangamo Therapeutics (NASDAQ:SGMO)
DateHeadline logoETFs with exposure to Sangamo Therapeutics, Inc. : May 25, 2017 - May 26 at 6:56 AM logoSangamo Therapeutics, Inc. :SGMO-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017 - May 25 at 2:17 AM logoSangamo Therapeutics Inc (SGMO) Receives Consensus Recommendation of "Hold" from Analysts - May 23 at 12:30 PM logoWill Sangamo Therapeutics (SGMO) Continue to Surge Higher? - May 18 at 12:46 PM logoSangamo Therapeutics Inc Expected to Post Q2 2017 Earnings of ($0.23) Per Share (SGMO) - May 18 at 8:01 AM logoSangamo's (SGMO) Hemophilia A Drug Gets Fast-Track Status - May 17 at 7:42 PM logoSangamo's (SGMO) Hemophilia A Drug Gets Fast-Track Status - May 17 at 7:42 PM logo Analysts Anticipate Sangamo Therapeutics Inc (SGMO) Will Announce Quarterly Sales of $3.88 Million - May 17 at 12:46 PM logoResearch Analysts Offer Predictions for Sangamo Therapeutics Inc's Q1 2018 Earnings (SGMO) - May 17 at 11:20 AM logoIs the Options Market Predicting a Spike in Sangamo Therapeutics (SGMO) Stock? - Nasdaq - May 17 at 8:01 AM logoZacks Investment Research Upgrades Sangamo Therapeutics Inc (SGMO) to "Hold" - May 16 at 10:18 AM logoSangamo Therapeutics Recognizes International MPS Awareness ... - PR Newswire (press release) - May 16 at 9:18 AM logoSangamo Receives Fast Track Designation From The FDA For SB-525 Investigational Hemophilia A Gene Therapy - May 16 at 9:18 AM logoSangamo Therapeutics Inc (SGMO) Receives "Neutral" Rating from Wedbush - May 16 at 8:14 AM logoSangamo Therapeutics Inc (SGMO) VP Curt A. Herberts III Sells 2,639 Shares - May 15 at 10:36 PM logoSangamo Biosciences (SGMO) Presents Recent Developments from Research and Clinical Programs at ASGCT - May 15 at 7:00 PM logoSangamo Therapeutics Recognizes International MPS Awareness Day And Celebrates The MPS I And MPS II Communities With Stories Of Hope - May 15 at 7:00 PM logo Brokerages Anticipate Sangamo Therapeutics Inc (SGMO) to Post -$0.28 EPS - May 15 at 9:26 AM logoHow These Biotech Stocks are Faring? -- Seattle Genetics, Sangamo Therapeutics, Vertex Pharma, and VIVUS - May 15 at 9:23 AM logoSangamo Therapeutics Presents Recent Developments from Research and Clinical Programs at Annual Meeting of the American Society of Gene & Cell Therapy - May 15 at 9:23 AM logoIs the Options Market Predicting a Spike in Sangamo Therapeutics (SGMO) Stock? - May 15 at 9:23 AM logoSangamo Therapeutics Inc (SGMO) Downgraded by Zacks Investment Research - May 14 at 7:04 PM logoSangamo Therapeutics' (SGMO) CEO Sandy Macrae on Q1 2017 Results - Earnings Call Transcript - Seeking Alpha - May 11 at 8:34 PM logoBUZZ-U.S. STOCKS ON THE MOVE- Snap Inc, Straight Path, Macy's, Sangamo - Nasdaq - May 11 at 8:34 PM logoWhy Sangamo Therapeutics Is Surging - 24/7 Wall St. - May 11 at 8:34 PM logoHere's Why Sangamo Therapeutics Rocketed Up to 56.3% Higher Today - May 11 at 8:33 PM logoSangamo Therapeutics, Inc. – Value Analysis (NASDAQ:SGMO) : May 11, 2017 - May 11 at 8:33 PM logoEdited Transcript of SGMO earnings conference call or presentation 10-May-17 9:00pm GMT - May 11 at 8:33 PM logoSangamo Therapeutics Reports First Quarter 2017 Financial Results - May 11 at 1:03 AM logoSangamo reports 1Q loss - May 11 at 1:03 AM logoSangamo Therapeutics Inc (SGMO) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS - May 10 at 11:24 PM logoSangamo Biosciences (SGMO), Pfizer (PFE) Enter Pact on ... - - May 10 at 8:02 PM logoSangamo Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : SGMO-US : May 9, 2017 - May 9 at 10:34 AM logoSangamo Biosciences (SGMO) Receives Special Regulatory Designations from FDA for Three Programs - May 4 at 8:07 PM logoSangamo Therapeutics (SGMO) Receives Daily Media Impact Rating of -0.15 - May 4 at 2:10 PM logoSangamo Therapeutics Announces Special Regulatory Designations from the FDA for Three Clinical Programs - PR Newswire (press release) - May 4 at 11:14 AM logoSangamo Therapeutics Announces Special Regulatory Designations from the FDA for Three Clinical Programs - May 4 at 11:14 AM logoSangamo Therapeutics Announces First Quarter 2017 Conference Call And Webcast - May 3 at 5:57 PM logoSangamo Therapeutics (SGMO) Earning Somewhat Critical Media Coverage, Study Finds - April 30 at 3:47 PM logoSangamo Therapeutics Inc (SGMO) Scheduled to Post Earnings on Monday - April 29 at 7:26 AM logoSangamo Therapeutics Inc (SGMO) Receives Average Recommendation of "Hold" from Analysts - April 28 at 2:18 PM logoSangamo Therapeutics (SGMO) Earns Daily News Impact Rating of 0.04 - April 27 at 10:00 PM logoShort Interest in Sangamo Therapeutics Inc (SGMO) Grows By 2.0% - April 27 at 12:12 PM logoSangamo Therapeutics Inc (SGMO) Expected to Announce Quarterly Sales of $3.94 Million - April 26 at 12:16 PM logoSangamo Biosciences (SGMO) Announces Retirement Of Founder Edward Lanphier From The Board Of Directors - April 26 at 9:24 AM logoSangamo Announces The Retirement Of Its Founder And Genome Editing Pioneer Edward Lanphier From The Board Of Directors - April 25 at 6:50 PM logoSangamo Therapeutics Announces Participation In The ARM 5th Annual Cell & Gene Therapy Investor Day - PR Newswire (press release) - April 25 at 9:53 AM logoSangamo Therapeutics Announces Participation In The ARM 5th Annual Cell & Gene Therapy Investor Day - April 24 at 6:14 PM logoSangamo Therapeutics Announces Presentations at 2017 Annual meeting of the American Society of Gene & Cell Therapy - April 24 at 6:14 PM logoSangamo Therapeutics (SGMO) Earns Daily Media Sentiment Rating of 0.31 - April 24 at 5:26 PM



Sangamo Therapeutics (SGMO) Chart for Saturday, May, 27, 2017

This page was last updated on 5/27/2017 by Staff